### **CIPF / Drug Discovery / Bioinformatics**




Structural Genomics Unit
Bioinformatics Department

Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain



### Data in the post-genomic era

Progress in science depends on new techniques, new discoveries and new ideas, probably in that order.



Sydney Brenner, 1980

The introduction and popularization of high-throughput techniques has drastically changed the way in which biological problems can be addressed and hypotheses can be tested.

But not necessarily the way in which we really address or test them...

Genes in the DNA...



...code for proteins...




>protein kunase

acctgttgatggcgacagggactgtatgctg atctatgctgatgcatgcatgctgactactgat

# From genotype to phenotype.

...whose structure accounts

...plus the environment...



Now: 22240 (NCBI build 35 12/04) 50-70% display alternative splicing

25%-60% unknown

**Transfrags** 

Genes in the DNA...



>protein kunase


acctgttgatggcgacagggactgtatgctgatctat gctgatgcatgcatgctgactactgatgtgggggcta ttgacttgatgtctatc.... ...which can be different because of the variability. 10 million SNPs



...whose final ffect configures the phenotype...

...when expressed in the proper moment and place...

A typical tissue is expressing among 5000 and 10000 genes




### From genotype to phenotype.

(post-genomics scenario)

...code for proteins...

That undergo posttranslational modifications, somatic recombination...

100K-500K proteins




...whose structures account for function...





...conforming complex interaction networks...


in cooperation with other proteins...


Each protein has an average of 8 interactions




















http://gepas.bioinfo.cipf.es
Gene Expression Pattern Analysis Suite

http://pupasuite.bioinfo.cipf.es SNP Analysis Suite

http://babelomics.bioinfo.cipf.es
Functional Profiling Analysis Suite







http://phylemon.bioinfo.cipf.es Molecular Evolution Analysis Suite





http://www.dbali.org
Structural Biology Analysis Suite








# Introduction to CM Modeling genomes Modeling Genes Tropical Disease Initiative

### Why is it useful to know the structure of a protein, not only its sequence?

- The biochemical function (activity) of a protein is defined by its interactions with other molecules.
- The biological function is in large part a consequence of these interactions.
- ♦ The 3D structure is more informative than sequence because interactions are determined by residues that are close in space but are frequently distant in sequence.





In addition, since evolution tends to conserve function and function depends more directly on structure than on sequence, **structure** is more conserved in evolution than sequence.

The net result is that patterns in space are frequently more recognizable than patterns in sequence.

### Principles of protein structure

GFCHIKAYTRLIMVG...







Folding (physics) *Ab initio* prediction

Evolution (rules)
Threading
Comparative Modeling

### protein prediction vs protein determination




### Comparative modeling by satisfaction of spatial restraints MODELLER



A. Šali & T. Blundell. J. Mol. Biol. 234, 779, 1993. J.P. Overington & A. Šali. Prot. Sci. 3, 1582, 1994. A. Fiser, R. Do & A. Šali, Prot. Sci., 9, 1753, 2000.

### Comparative modeling by satisfaction of spatial restraints Types of errors and their impact



Wrong fold



Miss alignments




**Loop regions** 




**Rigid body distortions** 




Side-chain packing





### Utility of protein structure models, despite errors




### **ModBase Statistics**

### Large-scale modeling of the TrEMBL-SWISSPROT databases

http://www.salilab.org/modbase/

Sequences (total)	2,186,210
Sequences (modeled)	1,340,687
Models	4,284,570





# What is the physiological ligand of Brain Lipid-Binding Protein?


Predicting features of a model that are not present in the template

BLBP/oleic acid

BLBP/docosahexaenoic acid

Cavity is not filled

Cavity is filled



- 1. BLBP binds fatty acids.
  - 2. Build a 3D model.
- 3. Find the fatty acid that fits most snuggly into the ligand binding cavity.

### Structural analysis of missense mutations in human BRCA1 BRCT domains

Nebojsa Mirkovic, Marc A. Marti-Renom, Barbara L. Weber, Andrej Sali and Alvaro N.A. Monteiro

Cancer Research (June 2004). 64:3790-97

Cannot measure the functional impact of every possible SNP at all positions in each protein! Thus, prediction based on general principles of protein structure is needed.



### Missense mutations in BRCT domains by function


cancer not cancer associated

?


no transcription activation

transcription activation

F1761S M1652K L1705PS1 L1657P M1775E C1697R 715NS172 R1699W E1660G M1775K H1686Q 2FF1734L A1708E L1780P R1699Q S1715R G1738EG I1807S K1702E P1749R V1833E 1743RA1 M1775R Y1703HF1 A1843T 752PF176 704S 11 V1665M D1692N G1706A M1652I D1733G A1669S M1775V P1806A A1823T W1718S M1652T R1751P C1787S V1833M V1653M R1751Q G1788D T1720A W1837R L1664P W1730S G1788V R1758G W1837G F1734S E1735K G1803A T1685A L1764P S1841N V1804D T1685I **I1766S** A1843P V1808A V1736A M1689R P1771L T1852S G1738R V1809A D1692Y P1856T D1739E V1809F T1773S F1695L D1739G P1859R V1810G P1776S V1696L D1739Y Q1811R R1699L D1778N P1812S V1741G G1706E D1778G N1819S H1746N W1718C D1778H M1783T




### Putative binding site on BRCA1



Williams *et al.* 2004 Nature Structure Biology. **June 2004 11**:519 Mirkovic *et al.* 2004 Cancer Research. **June 2004 64**:3790

### S. cerevisiae ribosome




Fitting of comparative models into 15Å cryo-electron density map.

43 proteins could be modeled on 20-56% seq.id. to a known structure.

The modeled fraction of the proteins ranges from 34-99%.

# The Nucleopore complex Cell evolution (?)



### **Tropical Disease Initiative (TDI)**

Predicting binding sites in protein structure models.










http://www.tropicaldisease.org

### Need is High in the Tail

- DALY Burden Per Disease in Developed Countries
- DALY Burden Per Disease in Developing Countries



Disease data taken from WHO, World Health Report 2004


DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

### Need is High in the Tail

- DALY Burden Per Disease in Developed Countries
- DALY Burden Per Disease in Developing Countries



Disease data taken from WHO, World Health Report 2004


DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance


DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

### Modeling Genomes

data from models generated by ModPipe (Eswar, Pieper & Sali)



### Comparative docking



### Summary table

models with inherited ligands


from 16,284 good models, 295 inherited a ligand/substance with at least one compound already approved by FDA and ready to be used from ZINC

	Transcripts	Good	Ligands	Lipinski	Lipinski+ZINC	FDA+ZINC
C. hominis	3,886	886	183	131	28	12 (10)
C. parvum	3,806	949	219	145	30	12 (10)
L. major	8,274	1,845	488	334	84	44 (34)
M. leprae	1,605	1,321	286	189	39	29 (25)
M. tuberculosis	3,991	2,887	404	285	71	44 (37)
P. falciparum	5,363	1,057	271	191	48	20 (16)
P. vivax	5,342	1,042	267	177	37	18 (15)
T. brucei	921	1,795	440	309	94	46 (36)
T. cruzi	19,607	3,915	730	493	127	62 (52)
T. gondii	7,793	587	174	124	28	8 (7)
TOTAL	60,588	16,284	3,462	2,378	586	295 (242)

### Example of inheritance (inheritance)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)

	Formula	Name	Cov.	Seq, Id. (%)	Residues
TSN	C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>	Trichostatin A	100.00	90.9	90 131 132 140 141 167
sнн	C <sub>14</sub> H <sub>20</sub> N <sub>2</sub> O <sub>3</sub>	Octadenioic acid hudroxyamide phenylamide	100.00	90.9	169 256 263 293 295



#### suberoylanilide hydroxamic acid

### **Pharmacological Action:**

Anti-Inflammatory Agents, Non-Steroidal
Antineoplastic Agents
Enzyme Inhibitors
Anticarcinogenic Agents

Inhibits histone deacetylase I and 3

ѕнн	ON H
0	


#### trichostatin A

#### **Pharmacological Action:**

Antibiotics, Antifungal
Enzyme Inhibitors
Protein Synthesis Inhibitors


chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription

	LmjF21.0680.1.pdb
Template	It64A
Seq. Id (%)	38.00
MPQS	1.47



### Example of inheritance (CDD-Roos-literature)

LmjF21.0680 from L. major "Histone deacetylase 2" (model 1)



Proc. Natl. Acad. Sci. USA Vol. 93, pp. 13143–13147, November 1996 Medical Sciences

### Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase

(cyclic tetrapeptide/Apicomplexa/antiparasitic/malaria/coccidiosis)

Sandra J. Darkin-Rattray\*†, Anne M. Gurnett\*, Robert W. Myers\*, Paula M. Dulski\*, Tami M. Crumley\*, John J. Allocco\*, Christine Cannova\*, Peter T. Meinke‡, Steven L. Colletti‡, Maria A. Bednarek‡, Sheo B. Singh§, Michael A. Goetz§, Anne W. Dombrowski§, Jon D. Polishook§, and Dennis M. Schmatz\*

Departments of \*Parasite Biochemistry and Cell Biology, <sup>‡</sup>Medicinal Chemistry, and <sup>§</sup>Natural Products Drug Discovery, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2004, p. 1435–1436 0066-4804/04/\$08.00+0 DOI: 10.1128/AAC.48.4.1435–1436.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Vol. 48, No. 4

Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors

### Acknowledgments

#### **Structural Genomics Unit (CIPF)**

Marc A. Marti-Renom

**Emidio Capriotti** 

Peio Ziarsolo Areitioaurtena

#### Comparative Genomics Unit (CIPF) Hernán Dopazo

Leo Arbiza

Francisco García

#### **Functional Genomics Unit (CIPF)**

Joaquín Dopazo

Fátima Al-Shahrour

José Carbonell

Ignacio Medina

**David Montaner** 

Joaquin Tárraga

Ana Conesa

Toni Gabaldón

Eva Alloza

Lucía Conde

Stefan Goetz

Jaime Huerta Cepas

Marina Marcet

Pablo Minguez

Jordi Burguet Castell

#### **FUNDING**

Prince Felipe Research Center Marie Curie Reintegration Grant STREP EU Grant Generalitat Valenciana

#### **Tropical Disease Initiative**

**Stephen Maurer (UC Berkeley)** 

Arti Rai (Duke U)

Andrej Sali (UCSF)

Ginger Taylor (TSL)

Barri Bunin (CDD)

#### STRUCTURAL GENOMICS

Stephen Burley (SGX)

John Kuriyan (UCB)

**NY-SGXRC** 

### **MAMMOTH**

**Angel R. Ortiz** 

### **BIOLOGY**

Jeff Friedman (RU)

James Hudsped (RU)

Partho Ghosh (UCSD)

**Alvaro Monteiro (Cornell U)** 

Stephen Krilis (St.George H)

#### **FUNCTIONAL ANNOTATION**

Fatima Al-Shahrour Joaquin Dopazo

### **COMPARATIVE MODELING**

Andrej Sali

M. S. Madhusudhan

Narayanan Eswar

Min-Yi Shen

**Ursula Pieper** 

Bino John

Maya Topf

#### **FUNCTIONAL ANNOTATION**

Andrea Rossi Fred Davis



http://bioinfo.cipf.es
http://squ.bioinfo.cipf.es